Biomm S.A.

São Paulo Stock Exchange BIOM3.SA

Biomm S.A. Cash and Short-Term Investments for the year ending December 31, 2023: USD 11.05 M

Biomm S.A. Cash and Short-Term Investments is USD 11.05 M for the year ending December 31, 2023, a -43.89% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Biomm S.A. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 19.70 M, a 99.49% change year over year.
Biomm S.A. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 9.87 M, a -63.82% change year over year.
Biomm S.A. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 27.30 M, a 4.94% change year over year.
Biomm S.A. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 26.01 M, a 14.90% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

São Paulo Stock Exchange: BIOM3.SA

Biomm S.A.

CEO	Mr. Heraldo Carvalho Marchezini
IPO Date	Jan. 11, 2000
Location	Brazil
Headquarters	Rua dos Pinheiros, 610
Employees	130
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Pet Food

Description

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

Key trends

Past 5 years